Norikazu Masuda

机构：Kyoto University, Kyoto University Hospital, Nagoya University · ORCID：0000-0002-7302-0278

发表论文 700 篇 · 总被引 31108 次 · h-index 65

代表论文

• Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02 (2025 · Annals of Oncology · 被引 7)
• Abstract P2-10-17: A randomized phase III study of first-line saruparib (AZD5305) + camizestrant vs CDK4/6i plus physician’s choice endocrine therapy or + camizestrant in patients w/ BRCA1/BRCA2/PALB2 mutations & HR+/HER2- advanced breast cancer (EvoPAR-Breast01) (2025 · Clinical Cancer Research · 被引 4)
• Precision Oncology Framework Using Circulating Tumor Cells (2025 · International Journal of Molecular Sciences · 被引 3)
• Future perspective of clinical usefulness of metabolic and mitochondrial heterogeneity in triple-negative breast cancers (2025 · International Journal of Clinical Oncology · 被引 2)
• A core outcome set for locoregional treatment reporting in neoadjuvant systemic breast cancer treatment trials (2025 · npj Breast Cancer · 被引 2)
• Health-related quality of life and physical activity collected via mobile application and wearable device in patients with HR +/HER2 − advanced breast cancer treated with palbociclib plus endocrine therapy or endocrine therapy alone: 6-month longitudinal study (JBCRG-26) (2025 · Breast Cancer · 被引 2)